• Ocuphire initiates phase 2 trial of oral diabetic retinopathy treatment

    8 days ago - By Healio

    Ocuphire Pharma has initiated a phase 2 clinical trial investigating APX3330 in nonproliferative and mild proliferative diabetic retinopathy, according to a press release.
    ZETA-1, a randomized, placebo-controlled, double-masked study, will investigate the efficacy of APX3330 over 24 weeks. The primary endpoint is the percentage of patients with a two or greater step improvement on the Diabetic Retinopathy Severity Scale. Secondary endpoints include an evaluation of central subfield thickness “to assess effects on diabetic macular edema, , safety and tolerability,”
    Read more ...